2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
2026 Pharmacy Benefit Manager Customer Satisfaction Report Webinar
PSG announces the results of the industry’s go-to report on pharmacy benefit manager (PBM) customer satisfaction, grounded in real-world perspectives from a wide range…
Read Post
2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
PSG Report Finds Specialty Drug Utilization is Dominant Driver of Trend, Biosimilar Adoption Reshaping the Market
New research also highlights double-digit specialty drug trend and major shifts among the top drugs by spend in 2025 DALLAS – July 23, 2026 – Pharmaceutical Strategies Group (“PSG”),…
Read Post
2026 Artemetrx State of Specialty Spend and Trend Report Webinar
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
2026 GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Join us for an in-depth exploration of one of the most impactful developments in prescription drug benefits: GLP-1 medications for type 2 diabetes and…
Read Post
PSG Report Finds Payers Reassessing GLP-1 Coverage, PBM Models, and Cost-Sharing Strategies
New research highlights affordability concerns, more interest in alternative approaches, and uncertainty around direct-to-consumer offerings DALLAS – June 9, 2026 – Pharmaceutical Strategies Group (“PSG”), an EPIC…
Read Post
Manage Pharmacy Spend and Trend: Artemetrx Analytics Overview
PSG’s Proprietary Data and Analytics Tool, Artemetrx Pharmacy benefit costs are shaped by a complex mix of spend drivers, utilization patterns, clinical decisions, and…
Read Post
PSG’s Perspective on AI in Healthcare and Pharmacy Benefits
Leveraging AI to Better Identify Fraud, Waste, and Abuse (FWA) Key Points Responsible AI implementation brings clarity to pharmacy benefit strategy when it is…
Read Post
Making Sense of GLP-1 Carve-Out Strategies
How Payers Can Adapt to the Rapidly Changing GLP-1 Landscape Key Points GLP-1 medications are driving rapid utilization growth that traditional pharmacy benefit designs are…
Read Post
Proactive PBM Oversight Protects Cost Savings During a Humira Biosimilar Transition
During a PBM transition, errors within a Humira biosimilar strategy cost three large employers a combined ~$750,000 in savings, which PSG quickly identified through…
Read Post